Imprimis announces launch of ICAN

Imprimis Pharmaceuticals this week announced that it has launched its new patient assistance program, Imprimis Cares Access Network (ICAN).

ICAN was developed to make the process of accessing Tiopronin Delayed Release easier.

"I have been taking Thiola for nearly 20 years and was relieved when I learned Imprimis Pharmaceuticals had introduced a lower-cost tiopronin alternative,” Imprimis Cares patient Sam S, 45, said. “The new Tiopronin-DR formulation is significantly more affordable for my employer, which is self-insured, and allows me to reduce the number of pills I take from 15 pills per day to six. I fully support the Imprimis Cares program and its mission of providing all Americans access to affordable prescription drugs. I am now enrolled in automatic refills to ensure my medication is delivered to my home each month. It has been a pleasure working with the Imprimis team and patient advocates during my changeover from Thiola to Tiopronin-DR and I cannot thank them enough for the time they devoted on my behalf to ensure access to this formulation now covered by my insurance."

Tiopronin is normally prescribed to treat cystine stones that have formed in the kidneys, ureters and bladders of patients with cystinuria.

Imprimis' tiopronin compounded formulations allow patients to reduce the number of pills they consume on a daily basis for this chronic genetic disease.